Please ensure Javascript is enabled for purposes of website accessibility
ホーム > 製品 > 抗体 > 中和抗体

InVivoMAb Anti-ZEBOV Glycoprotein Antibody (6D8) (VK623040)

InVivoMAb Anti-ZEBOV Glycoprotein Antibody (6D8)
InVivoMAb Anti-ZEBOV Glycoprotein Antibody (6D8)
価格(USD):
スペック:
  • 100ug
  • 1mg
数量:
お問い合わせ
  • 概要

  • イメージ

  • 参考文献

  • データシート

  • SDS

概要
カタログ番号VK623040
説明
InVivoMAb Anti-ZEBOV GP/Envelope glycoprotein Antibody (6D8) [6D8] (VK623040) is a human monoclonal antibody detecting Envelope glycoprotein in ELISA, IP, Neutralization, WB.
Highlights
  • ●Multi-Application — Validated across multiple applications.
種反応性Zaire ebolavirus (ZEBOV) (Zaire Ebola virus)
アプリケーションELISA, IP, Neutralization, WB
宿主種Human
クローン性Monoclonal
アイソタイプIgG1, kappa
クローンID6D8
ターゲット Envelope glycoprotein, GP, GP1, GP1,2, GP1,2-delta, GP2, Shed GP
エンドトキシンレベル < 1 EU/mg
純度 >95% as determined by SDS-PAGE.
関連製品 pH 7.4 Dilution Buffer
精製 Protein A/G purified from cell culture supernatant.
アクセッション番号 Q05320
形態 Liquid
保存バッファー 0.01M PBS pH 7.4.

データシートのハードコピーまたはロット固有のCOAに記載された具体的なバッファー情報を参照してください。

安定性と保存 Use a manual defrost freezer and avoid repeated freeze thaw cycles. Store at 2 to 8°C for frequent use. Store at -20 to -80°C for twelve months from the date of receipt.
背景

Envelope glycoprotein (GP) is a ~74 kDa protein. Trimeric GP1,2 complexes form the virion surface spikes and mediate the viral entry processes, with GP1 acting as the receptor-binding subunit and GP2 as the membrane fusion subunit. At later times of infection, down-regulates the expression of various host cell surface molecules that are essential for immune surveillance and cell adhesion. Down-modulates several integrins including ITGA1, ITGA2, ITGA3, ITGA4, ITGA5, ITGA6, ITGAV and ITGB1. This decrease in cell adhesion molecules may lead to cell detachment, contributing to the disruption of blood vessel integrity and hemorrhages developed during infection (cytotoxicity) (Probable). Interacts with host TLR4 and thereby stimulates the differentiation and activation of monocytes leading to bystander death of T-lymphocytes.

1. Simmons, G. et al. (2002) Journal of virology 76, 2518-28. PMID: 11836430
2. Takada, A. et al. (2000) Virology 278, 20-6. PMID: 11112476
3. Iampietro, M. et al. (2017) PLoS pathogens 13, e1006397. PMID: 28542576
4. Edri, A. et al. (2018) Frontiers in immunology 9, 1428. PMID: 30013549
5. Vande Burgt, NH. et al. (2015) Viruses 7, 5587-602. PMID: 26516900
6. Brinkmann, C. et al. (2016) Journal of virology 90, 11075-11086. PMID: 27707924
7. González-Hernández, M. et al. (2018) Journal of virology 92. PMID: 29669839
8. Rizk, MG. et al. (2017) Journal of virology 91. PMID: 28878074
注意事項 For research use only. Not suitable for clinical or therapeutic use.
イメージ
  • InVivoMAb Anti-ZEBOV Glycoprotein Antibody (6D8)

    SDS-PAGE

    SDS-PAGE for InVivoMAb Anti-ZEBOV GP/Envelope glycoprotein Antibody (6D8).

参考文献
Formula
Mass (g) = Concentration (mol/L) × Volume (L) × MW (g/mol)
Enter any 2 of Mass, Concentration, Volume + Molecular Weight to solve for the unknown.
Mass
=
Concentration
×
Volume
Molecular Weight *
g/mol
Formula
C₁ × V₁ = C₂ × V₂
Enter any 3 of the 4 values to solve for the unknown.
Stock Solution
C₁ (Stock Conc.)
×
V₁ (Stock Vol.)
=
Working Solution
C₂ (Working Conc.)
×
V₂ (Working Vol.)
レコメンデーション

お問い合わせ カスタムクォート、大量リクエストおよびその他の問題については

メール: [email protected]

ディストリビューターリスト